thank stand time would like welcome everyone iqvia third quarter earn conference call line place mute prevent background noise speaker remark question answer session operator instruction reminder call record thank would like hand conference speaker today child senior vice president investor relation corporate communication child please begin conference child senior vice president financial plan analysis thank good morning everyone thank join third quarter earn call today chairman chief executive officer executive vice president chief financial officer executive vice president general counsel senior vice president financial plan analysis associate director investor relation today reference presentation visible call webcast presentation also available follow call event presentation section iqvia investor relation website iqvia begin would like caution listener certain information discuss management conference call include forward look statement actual result could differ materially state imply forward look statement risk uncertainty associate company business discuss company file security exchange commission include annual report form subsequent file addition certain financial measure call consider supplement substitute financial measure prepare accordance reconciliation measure comparable measure include press release conference call presentation would like turn call chairman chairman chief executive good morning everyone thank join today third quarter result strong momentum earlier year continue despite resurgence delta variant impact operation learn manage disruption outlook longer term remain unchanged backdrop life science industry continue strong biotech fund continue record level national venture capital association fund total billion already exceed full year pipeline late stage molecule continue expand time high almost molecule active phase phase development clinical trial start trend ahead recent year year date start finally drug approval keep pace historically high level drug approve year date stage strong volume upcoming commercial launch bottom line dynamic industry strong remain bullish outlook market iqvia particular think longer term plan want remind upcoming analyst investor conference city meet provide financial guidance ahead usual timeline normally coincide year result early share term outlook plan next phase iqvia growth look forward everyone hope join review third quarter revenue third quarter grow report basis constant currency million midpoint guidance range beat drive primarily higher throughs know dilute margin somewhat stronger organic revenue growth third quarter adjust grow reflect revenue growth productivity measure million phonetic beat point guidance range entirely stronger operational performance third quarter adjust dilute grow midpoint guidance beat come adjust drop favorability line item provide update business real world evidence business continue take lead role inform healthcare late release drug guidance electronic health record medical claim data support regulatory decision make cite several iqvia publication growth rare disease therapy personalize medicine drive trial number single clinical trial increase every year external comparators provide important context study regulator payer client recognize lead expertise area example recent major deliver external comparator cardiovascular study pharma client another example award year follow study demonstrate long term effectiveness safety newly launch gene therapy regulatory guidance require extend follow patient expose cell gene therapy iqvia innovative real world capability combine direct patient solution iqvia technology platform capture secondary data pivotal award technology front suite offer continue adopt marketplace familiar platform commercial technology application course continue expand footprint client quarter bring total number date customer also excite increase adoption orchestrate clinical trial suite quarter example lead biotechnology company select site portal module within power site engagement across trial customer site portal module represent site active study site portal module similarly award platform continue experience strong demand successfully deploy project across different therapeutic area date customer platform include eight pharma client platform process million unique patient response country across language want word grow part industry familiar trial iqvia trial offer combine several module within suite include telemedicine connect device service capability include home nurse along trial patient study coordinator organize around trial platform importantly develop innovative clinical patient engagement offer include direct patient service accelerate recruitment improve patient diversity inclusion clinical trial step back look grow importance portfolio find active full service trial utilize component offer competitor speak offer often report business look trial actually fully utilize capability mean fully trial platform award trial date total billion award unique sponsor multiple trial ongoing trial spend different therapeutic area unique indication recruit patient country ability combine advance clinical technology extensive network investigator care professional differentiate space make partner choice trial utilize full capability overall business continue build strong momentum approximately billion book quarter bring book first time billion include throughs result contract book bill ratio include throughs exclude throughs contract book bill ratio include throughs exclude throughs contract backlog include throughs grow year year billion result next month revenue backlog increase billion million sequentially versus second quarter signal several time past ramp investment capability recently announce open square foot innovation laboratory north facility provide customer access edge bioanalytical vaccine genomics capability along expansion exploratory human biomarker discovery service service enable partner closely sponsor development essential biomarkers support molecule move clinical development throughout life cycle expansion course come investment announce last quarter square foot facility turn detail financial performance executive vice president chief financial thank good morning everyone start review revenue third quarter revenue million grow report basis constant currency year date revenue million grow report constant currency technology analytics solution revenue third quarter million report constant currency year date technology analytics solution revenue million report constant currency third quarter solution revenue million actual rate constant currency exclude impact throughs third quarter revenue grow year year year date revenue solution million report constant currency finally contract sale medical solution revenue million report constant currency year date revenue million grow report constant currency move adjust million third quarter year date adjust million grow year year third quarter income million dilute earn share year date income million earn dilute share adjust income million third quarter adjust dilute earn share grow year date adjust income million share turn solution backlog already review solution deliver another outstanding quarter business backlog stand billion last month book include throughs rise billion okay turn balance sheet cash cash equivalent total billion debt billion result debt billion leverage ratio come time trail month adjust cash flow quite strong third quarter cash flow operation million capex million result free cash flow million third quarter performance bring free cash flow year date first three quarter almost billion continue strong improvement trend past three year quarter repurchase million share million share repurchase authorization remain latest program okay turn guidance raise full year revenue guidance million midpoint reflect third quarter strength continue operational momentum business revenue guidance million million represent year year growth note include guidance million headwind versus previous guidance look comparison prior year tailwind basis point full year revenue growth also raise profit guidance result stronger revenue outlook increase full year adjust guidance million midpoint full year guidance million million represent year year growth move increase adjust guidance midpoint guidance range represent year year growth full year guidance assume foreign currency rate remain effect balance year full year guidance imply fourth quarter guidance show number context probably recall last year fourth quarter unusual snap back general business rebound effect pick incremental demand mega vaccine study government relate work within fourth quarter revenue expect million million represent growth quarter headwind growth basis point expect fourth quarter revenue growth single digit reflect expect year year decline government relate work drag note though underlie constant currency organic growth high single digit level recently accelerate revenue growth would teen service growth teen despite last year difficult comparison vaccine work slightly adjust fourth quarter expect million million adjust dilute expect grow summary deliver strong third quarter strong result result bottom line backlog improve billion year year next month revenue backlog increase billion million sequentially versus second quarter report another strong quarter free cash flow million first three quarter year market improvement prior year finally raise full year guidance revenue adjust adjust dilute hand back operator question answer